Trial Profile
A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-or second-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer (MBC) who have received trastuzumab and endocrine therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Anastrozole; Exemestane; Letrozole; Trastuzumab
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALTERNATIVE
- Sponsors GlaxoSmithKline Research & Development; Novartis
- 01 Jul 2022 This trial has been completed in Hungary (End Date: 06 Jun 2022), according to European Clinical Trials Database record.
- 25 Jun 2022 This trial has been discontinued in Ireland, according to European Clinical Trials Database record.
- 10 Jun 2022 Status changed from active, no longer recruiting to completed.